Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Markets Earnings Roundup: BMS, Pfizer (Part 2)

This article was originally published in PharmAsia News

Executive Summary

BMS elaborated on its plans to ease out of the emerging market explosion in demand for diabetes treatments as it moves to develop new therapies in immune-oncology. Pfizer saw China revenues rise smartly in the fourth quarter and Lipitor sales standout in emerging markets.

You may also be interested in...

The Specter Of Spin-off Plans Dominates Pfizer Year-end Earnings

Although the company beat estimates and executed on an ambitious late-stage pipeline, analysts on Pfizer’s earnings call were focused on palbociclib, Prevnar, and the pharma’s plans for its established products business.

Spectacular Market Launches Key To Enduring Success Of Brands In APAC - IMS Health

MUMBAI - Following studies on the launch of patented brands in the Asia-Pacific market, IMS Health said less than 20 percent of brands perform well if they do not strike significant success within the first six months of their launches

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts